All samples·Sample analysis

Get your own pass — $199

radioligand therapy for prostate cancer OrganizationsSLOAN-KETTERING INST CAN RESEARCH

SLOAN-KETTERING INST CAN RESEARCH

Projects attributed to SLOAN-KETTERING INST CAN RESEARCH within this analysis sample.

In This Analysis

Projects

10

NIH Funding

$8.1M

Projects(10)

Project	PI	Category	Funding
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy R01CA262675	PILLARSETTY, NAGAVARAKISHORE	Therapeutics	$2.0M
Clinical Qualification of Imaging and Fluid-Based Tumor Monitoring Biomarkers for Metastatic Castration Resistant Prostate Cancer 5R01CA240759-06	SCHWARTZ, LAWRENCE H	Therapeutics	$1.7M
Theranostic DLL3/PSMA-bi-specific CAR-T cells for prostate cancer therapy 5R01CA287491-02	PONOMAREV, VLADIMIR	Therapeutics	$1.4M
Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate R01CA286918	BODEI, LISA (contact)	Basic Research	$1.4M
Improving efficacy of radioiodine treatment of thyroid cancer 5R01CA249663-05	FAGIN, JAMES A	Therapeutics	$919K
PSMA ligand radiosensitizers to improve the therapeutic index of external beam radiotherapy for prostate cancer 5R03CA286680-02	HIGGINSON, DANIEL	Therapeutics	$176K
Targeting androgen receptor with non-steroidal next-generation radiopharmaceuticals K99CA312787	JALLINOJA, VILMA I.	Training	$153K
Precision Radiotheranostics Targeting Oncogenic Mutations K99CA307864	KLAUSER, PAUL CHUANG	Training	$151K
Leveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate Cancer R35CA232130	LEWIS, JASON S. (contact)	Therapeutics	$133K
Targeting the DNA Damage Repair Pathway in Non-Castrate Prostate Cancers P01CA228696	SCHER, HOWARD I (contact)	Therapeutics	—

See SLOAN-KETTERING INST CAN RESEARCH’s full platform profile

Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.